NEUROENDOCRINE CARCINOMA

This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone…

This study tests a combination of two drugs—nivolumab (an immunotherapy that helps the immune system fight cancer) and temozolomide (a chemotherapy drug)—in people with small-cell lung cancer that has returned or stopped responding to treatment, or advanced neuroendocrine tumors.…

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancer that has DLL3 protein. The goal is to find the safest dose and see how well the body handles it. About 232 adults will take part in th…

This study tests a cancer-killing virus (VSV-IFNβ-NIS) given with an immunotherapy drug (pembrolizumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine cancer, and kidney cancer. The goal is to find the safest and most effective virus do…

This study tests an experimental drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The goal is to see if the drug can slow tumor growth or shrink tumors. Participants take the drug by mouth, and their progress is…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in people with rare solid tumors that are hard to treat. The goal is to see if the drugs can shrink or control the cancer by boosting the immune system and blocking tumor blood supply. About 133 adults wit…

This study tests two drugs together—niraparib and dostarlimab—for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. The goal is to see if the combination can shrink tumors or slow the disease. About 48 adults will take p…

This study is creating a registry of 400 people with neuroendocrine tumors (NETs). Researchers will collect blood samples and health data over time to see if certain biomarkers can help detect tumors earlier, predict treatment response, and monitor for recurrence. The goal is to …

This study follows over 2,500 people with neuroendocrine tumors (NETs) to learn how symptoms and treatments affect their quality of life. Participants fill out surveys about their well-being and care experiences for up to 18 months. The goal is to find which treatments work best …